Earnings Call · Q3 FY2021·2021-11-08

Q3 21EPS +65.38%·Rev n/aQ2 21EPS +10.00%·Rev n/aQ1 21EPS +20.75%·Rev n/aQ4 20EPS +10.64%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Mark Johnson — Vice President of Investor Relations

Stephen Davis — Chief Executive Officer

Brendan Teehan — Senior Executive (likely Head of Commercial or similar) based on commercial performance discussion

Serge Stankovic — Senior Executive (likely Chief Medical Officer or similar) based on regulatory and clinical discussion

Mark Schneyer — Senior Executive (likely Chief Financial Officer or similar) based on financial results discussion

+10.2%1d on move date+10.6% vs SPY3d+5.7%5d+1.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access